ProNAi Therapeutics Obtains $59,500,000 Series D Round

  • Feed Type
  • Date
    4/22/2014
  • Company Name
    ProNAi Therapeutics
  • Mailing Address
    46701 Commerce Center Drive Plymouth, MI 48170 USA
  • Company Description
    ProNAi Therapeutics, Inc. is an emerging biopharmaceutical company that is leveraging its novel and proprietary nucleic acid-based interfering technology, DNAi, to advance a next generation of therapies for patients with cancer and other complex genetic diseases.
  • Website
    http://www.pronai.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $59,500,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    The Series D funding will be used to advance PNT2258 in several Phase II clinical studies in patients with relapsed or treatment refractory non-Hodgkin’s lymphoma including those with diffuse large B-cell lymphoma (DLBCL),Richter’s transformation, and follicular lymphoma (FL). Proceeds will also be used to support drug manufacturing, advance development of preclinical drug candidates, and build ProNAi’s organization in Michigan.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy